Orforglipron
Weight LossPreclinicalOrforglipron (also known as LY3502970) is Eli Lilly's investigational oral, non-peptide, small-molecule glucagon-like peptide-1 (GLP-1) receptor agonist for the treatment of obesity and type 2 diabetes. Unlike virtually every other GLP-1 receptor agonist on the market — Semaglutide, Tirzepatide, Liraglutide, Dulaglutide, exenatide — which are peptide-based and require either subcutaneous injection or strict oral dosing conditions to survive gastric degradation, orforglipron is a small molecule with a molecular weight of approximately 563 Daltons.
Overview
At A Glance
Orforglipron engages the GLP-1 receptor through an allosteric binding mechanism fundamentally different from native GLP-1 or peptide-based analogs.…
Mechanism of Action
Orforglipron engages the GLP-1 receptor through an allosteric binding mechanism fundamentally different from native GLP-1 or peptide-based analogs.
Allosteric GLP-1 Receptor Agonism: Native GLP-1 is a 30-amino-acid peptide that binds the GLP-1 receptor (GLP1R) orthosteric site — the same pocket occupied by semaglutide, liraglutide, and other peptide analogs. Orthosteric peptide agonists achieve full receptor activation by mimicking the natural ligand's 3D conformation. Orforglipron, in contrast, binds at a topographically distinct allosteric site on GLP1R, stabilizing the receptor in an active conformation that triggers downstream signaling without needing to occupy the orthosteric pocket (Kawai et al., 2020).
Full Agonist Activity: Despite binding allosterically, orforglipron achieves full agonist efficacy — meaning it produces the same maximum receptor activation as native GLP-1 or semaglutide, not partial activation. This was not a priori guaranteed; many allosteric modulators are "biased agonists" that activate only a subset of downstream pathways. Orforglipron activates the canonical Gαs/cAMP/PKA pathway that drives:
- Beta-cell insulin secretion (glucose-dependent)
- Alpha-cell glucagon suppression
- Hypothalamic POMC/CART neuron activation (appetite suppression)
- Brainstem vagal nucleus satiety signaling
- Gastric emptying delay
Pharmacokinetic Profile: Orforglipron's key PK features enable once-daily oral dosing:
- Oral bioavailability: ~10-15% (vs semaglutide's ~0.8-1% when given as Rybelsus tablets, requiring SNAC absorption enhancer)
- Half-life: ~29-49 hours — long enough for once-daily steady-state dosing
- Tmax: ~6-10 hours after oral administration
- Not a substrate for peptidase DPP-4 (since it's not a peptide)
- Not subject to gastric acid degradation (small molecule chemical stability)
- No food-effect: absorption not meaningfully affected by meals, solving the #1 compliance problem with oral semaglutide (Rybelsus requires fasting + 30-minute wait before eating)
Metabolic Effects (downstream of receptor activation): Once orforglipron activates GLP1R, the downstream physiology is essentially identical to semaglutide or other GLP-1 agonists:
- Weight loss: primarily via appetite suppression and reduced food intake (~400-600 kcal/day caloric deficit at therapeutic doses)
- Glycemic control: ~1.5-2% HbA1c reduction in T2D via glucose-dependent insulin secretion and glucagon suppression
- Gastric emptying: delayed by ~30-60 minutes at peak doses, contributing to satiety
- Cardiovascular: probable reduction in MACE (major adverse cardiovascular events) based on GLP-1 class effect — ATTAIN-1 and dedicated CV outcomes trials ongoing
Why "Non-Peptide" Matters: Beyond manufacturing advantages, the small-molecule structure resists the immunogenicity risk that occasionally affects peptide drugs (anti-drug antibody formation), and may achieve better penetration into CNS regions where peptide drugs have limited blood-brain-barrier permeability. However, the central antiobesity effects of peptide GLP-1s are already strong, so any CNS PK advantage may be marginal.
Relation to Injectable GLP-1 Class: Orforglipron is not structurally related to exendin-4, GLP-1, or semaglutide — it was identified through high-throughput screening followed by medicinal chemistry tuning, producing a novel chemotype that happens to activate the same receptor. This is analogous to how small-molecule opioid agonists (fentanyl, oxycodone) activate the same receptors as endogenous peptide opioids (endorphins, enkephalins) without sharing their peptide structure.
Overview
Orforglipron (also known as LY3502970) is Eli Lilly's investigational oral, non-peptide, small-molecule glucagon-like peptide-1 (GLP-1) receptor agonist for the treatment of obesity and type 2 diabetes. Unlike virtually every other GLP-1 receptor agonist on the market — Semaglutide, Tirzepatide, Liraglutide, Dulaglutide, exenatide — which are peptide-based and require either subcutaneous injection or strict oral dosing conditions to survive gastric degradation, orforglipron is a small molecule with a molecular weight of approximately 563 Daltons. It binds the GLP-1 receptor at an allosteric site distinct from the orthosteric site used by the native peptide, producing full agonist activity without needing the peptide's complex 3D structure. This pharmacology delivers two transformational advantages: (1) it can be taken as a once-daily pill without food or beverage restrictions, and (2) it does not require refrigeration, cold-chain distribution, or manufacturing capacity constrained to specialized peptide synthesis — solving two of the biggest barriers to global GLP-1 access.
Orforglipron's Phase 3 ACHIEVE and ATTAIN programs completed primary readouts in 2025, with results that effectively validate oral non-peptide GLP-1 receptor agonism as clinically equivalent to injectable peptide analogs. In ATTAIN-1 (obesity), 36 mg orforglipron once daily produced mean weight loss of 14.7% at 72 weeks in adults with obesity but without diabetes — remarkably close to the 15-17% typical of subcutaneous semaglutide 2.4 mg weekly (Wegovy) and within striking distance of tirzepatide's 15-20% range at comparable doses. In ACHIEVE-1 (type 2 diabetes), orforglipron at 12 mg, 24 mg, and 36 mg doses delivered HbA1c reductions of ~1.3%, ~1.6%, and ~1.8% respectively over 40 weeks, alongside 4-8% weight loss. These results position orforglipron as the first oral non-peptide GLP-1 to demonstrate injectable-class efficacy, setting up probable FDA and EMA filings in 2025-2026 with potential first approvals in 2026.
Why this matters commercially and clinically: the current GLP-1 supply crisis — semaglutide shortages lasted 2+ years, tirzepatide manufacturing is still constrained — stems from peptide synthesis capacity. Small-molecule orforglipron can be manufactured in traditional API facilities using standard organic chemistry, dramatically expanding global supply, reducing cost-of-goods, and enabling distribution to low- and middle-income countries where refrigerated peptides are logistically difficult. A generic-analog small-molecule GLP-1 class could ultimately bring retail cost from $1,000+/month for brand-name injectables to potentially under $50/month for oral generics — with parallels to how statins democratized cholesterol management. Cross-references include Semaglutide (injectable GLP-1 peptide), Tirzepatide (injectable GLP-1/GIP peptide), Mazdutide (injectable GLP-1/glucagon peptide for China), Retatrutide (injectable GLP-1/GIP/glucagon triple agonist peptide), and Cagrilintide (amylin analog used in combination with GLP-1s).
Chemical Information
IUPAC Name
Not yet available
CAS Number
Not yet available
Molecular Formula
Not yet available
Molecular Mass
Not yet available
Chemical data is being compiled for this compound.
Dosing & Protocols
Unlock Dosing Protocols
Free account gets you:
- View beginner, intermediate & advanced protocols
- See weight-based dosing calculations
- Access cycle length & frequency data
2,800+ researchers already in
Research
Unlock Research Data
Free account gets you:
- Browse PubMed study summaries
- See clinical trial phases & results
- Access mechanism of action details
2,800+ researchers already in
Interactions
Contraindications
Absolute Contraindications:
- Personal or family history of medullary thyroid carcinoma (MTC) — boxed warning shared across GLP-1 class
- Multiple Endocrine Neoplasia syndrome type 2 (MEN2) — boxed warning
- Prior serious hypersensitivity to orforglipron or its components
- Pregnancy (insufficient safety data; discontinue at least 2 months before conception)
- Active lactation (insufficient safety data)
Relative Contraindications (Use With Caution / Individualized Assessment):
- History of pancreatitis (acute or chronic) — weigh benefits vs. risk of recurrence
- Active gallbladder disease / symptomatic cholelithiasis — rapid weight loss increases gallstone risk
- Severe gastroparesis or known gastric outlet obstruction
- Severe chronic kidney disease (eGFR <30 mL/min/1.73m²) — limited safety data
- Severe hepatic impairment (Child-Pugh C) — limited safety data
- Active eating disorder (especially anorexia nervosa or restrictive subtypes)
- Type 1 diabetes mellitus — orforglipron is for T2D and obesity; no established role in T1D and risk of DKA if insulin inappropriately reduced
- Diabetic retinopathy — rapid glycemic improvement can temporarily worsen retinopathy; ophthalmologic surveillance during initiation
Drug Interactions Requiring Special Caution:
- Insulin, sulfonylureas, meglitinides — significant hypoglycemia risk; reduce doses at initiation
- Warfarin — potential altered absorption; increased INR monitoring
- Oral contraceptives — possible altered absorption during first 4 weeks; backup contraception recommended
- Drugs with narrow therapeutic index and gastric-emptying-dependent absorption (e.g., digoxin) — monitor levels
Pre-Surgical Considerations: Patients on GLP-1 agonists (including anticipated for orforglipron) have delayed gastric emptying that may persist longer than standard pre-operative fasting periods. The American Society of Anesthesiologists (2023 guidance) recommends:
- Hold orforglipron for at least 1-2 weeks before elective surgery requiring anesthesia (if feasible), OR
- Use extended pre-op fasting (≥8 hours for solids, ≥4 hours for clear liquids), OR
- Consider rapid sequence induction to minimize aspiration risk
- Gastric ultrasound assessment of residual contents may be helpful
For urgent/emergent surgery, anesthesiologists should assume full stomach and take aspiration precautions.
Weight Loss Monitoring: While orforglipron is designed for weight loss, excessive loss (>1.5-2 lb/week beyond initial water weight) may indicate:
- Inadequate caloric intake due to severe appetite suppression
- Possible underlying GI pathology
- Need for dose reduction
Extreme weight loss with poor nutritional intake can compromise lean mass, bone density, immune function, and menstrual cyclicity (in women of reproductive age).
Mental Health Considerations: While FDA and EMA have not identified a causal link between GLP-1 agonists and suicidal ideation/behavior in complete analyses, individual case reports exist. Patients with:
- Active major depression
- History of suicidal ideation or self-harm
- Complex relationship with food / body image issues Should be monitored with mental health support; orforglipron is not absolutely contraindicated but requires thoughtful management.
Sports and Athletics: GLP-1 agonists are not currently banned by WADA (World Anti-Doping Agency) or most sporting bodies as of 2026, but athletes should:
- Verify current prohibited list
- Ensure adequate caloric intake for training demands
- Monitor body composition to preserve lean mass and performance
- Work with sports dietitian to periodize nutrition around training
Long-Term Safety Unknowns: As with all newly approved medications, long-term (>10 year) safety data for orforglipron will accumulate post-approval. Current Phase 3 data extends to ~72 weeks of continuous exposure. Areas of ongoing surveillance:
- Thyroid cancer incidence (MTC-specific)
- Pancreatic cancer incidence
- Gallbladder disease rates
- Bone density changes
- Mental health outcomes
- Effects on cognitive function
- Reproductive/fertility effects
Research Disclaimer
This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds.
$249.99
—
1
1
capsule
| Vendor | Product | Form | Qty | Price | $/mg | Coupon | |
|---|---|---|---|---|---|---|---|
 |
Orforglipron Capsules 30ct | capsule | 30 capsules● In Stock | $249.99BEST | — |
Tracking since Apr 6, 2026 · 1 data point
Vendors Selling Orforglipron
How we score these vendors
Every supplier above is graded 0–100 on COA verification, payment transparency, shipping, reviews, and active listings. Methodology published, no pay-to-rank.
Related Compounds
View All5-Amino-1MQ
Weight LossPreclinical5-Amino-1MQ (5-amino-1-methylquinolinium iodide) is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme that transfers a methyl group from S-adenosyl-L-methionine (SAM) to nicotinamide to form 1-methylnicotinamide (1-MNA) and S-adenosyl-L-homocysteine (SAH).
BAM15
Weight LossPreclinicalBAM15 is a small-molecule mitochondrial protonophore uncoupler that was first described in 2014 as a tool compound for dissipating proton motive force selectively across the inner mitochondrial membrane without collapsing the plasma membrane electrochemical gradient (Kenwood et al., 2014).
Exenatide
Weight LossPreclinicalGLP-1 receptor agonist used for metabolic effect and appetite regulation..
L-Carnitine
Weight LossPreclinicalL-Carnitine is a naturally occurring quaternary ammonium compound synthesized in the body from the amino acids lysine and methionine, with essential cofactor roles in fatty acid metabolism, energy production, and cellular health.
Lipo-C
Weight LossPreclinicalLipotropic compound blend injection.
Mazdutide
Weight LossPreclinicalMazdutide (also known as IBI362, Lilly compound LY3305677) is a dual glucagon-like peptide-1 (GLP-1) and glucagon receptor agonist originally discovered by Eli Lilly and exclusively licensed to Innovent Biologics in 2019 for development and commercialization in Mainland China, Hong Kong, Macau, and Taiwan.
Side-by-Side Comparisons
All ComparisonsView Full Dosage Guide →
Protocols, calculator & safety for Orforglipron
Related Articles
All PostsAquasome Nanotechnology and Oral Peptides: The Mechanism, the Research, and the 10 Compounds It Actually Works For
how aquasome 3-layer nano-encapsulation lets peptides like retatrutide, bpc-157, and tb-500 survive the gut. pubmed-backed deep dive on the 10 compounds it works for.
5/20/2026Retatrutide Protocol Guide 2026: Dosing, Titration, Side Effects, Week-by-Week
A standalone beginner protocol for retatrutide — Eli Lilly's triple GLP-1/GIP/glucagon agonist. Dose math, week-by-week titration, side-effect management, realistic expectations, and where to source research-grade material.
5/19/2026Research Score
0 PubMed studies
Quality Indicators
Data Completeness
63%Quick Facts
Trial Phase
Preclinical
Research Disclaimer
This information is for educational and research purposes only. Not intended as medical advice. Consult a healthcare professional before use.
Frequently Asked Questions
What makes orforglipron different from oral semaglutide (Rybelsus)?
Orforglipron is a small-molecule non-peptide drug with ~10-15% oral bioavailability, allowing it to be taken anytime with or without food. Rybelsus is oral semaglutide — still a peptide — requiring an absorption enhancer (SNAC), strict fasting (8+ hours pre-dose), and a 30-minute wait before eating or drinking anything afterward. These practical differences translate to massive efficacy gaps: orforglipron produces ~14-15% weight loss at 72 weeks versus Rybelsus's ~3-5%, primarily because consistent daily compliance is achievable with orforglipron and impractical for many patients on Rybelsus (Pratt et al., 2022).
How does orforglipron's weight loss compare to injectable semaglutide or tirzepatide?
Phase 3 ATTAIN-1 showed orforglipron 36 mg daily produced ~14-15% weight loss at 72 weeks, closely comparable to semaglutide 2.4 mg weekly (Wegovy) which produces ~15-17% at 68 weeks in STEP-1. Tirzepatide 15 mg weekly (Zepbound) remains higher at ~20-22% at 72 weeks in SURMOUNT-1 due to dual GLP-1/GIP agonism. So orforglipron matches semaglutide and approaches tirzepatide — remarkable for an oral drug — but tirzepatide's dual receptor approach retains an efficacy edge. For a patient who refuses injections, orforglipron is now a viable alternative at near-semaglutide efficacy.
When will orforglipron be available by prescription?
Eli Lilly disclosed plans for FDA and EMA regulatory submissions in late 2025 for both obesity and type 2 diabetes indications. Assuming standard priority review timelines, first approvals are expected in 2026 with commercial launch in 2026-2027. Initial supply may be constrained as manufacturing scales, similar to early semaglutide/tirzepatide launches — though because orforglipron is a small molecule, manufacturing capacity should expand much more quickly than peptide analogs.
How is orforglipron's allosteric mechanism different from other GLP-1 agonists?
All peptide GLP-1 agonists (semaglutide, liraglutide, tirzepatide) bind the GLP-1 receptor at its orthosteric site — the same location native GLP-1 uses. Orforglipron binds at a topographically separate allosteric site on the same receptor, still producing full downstream activation. This allows a small-molecule non-peptide chemical structure to achieve peptide-equivalent efficacy at the receptor level. The allosteric mechanism was validated in structural biology and functional pharmacology studies (Kawai et al., 2020). Clinically, downstream effects — insulin secretion, appetite suppression, gastric emptying delay — are essentially identical to orthosteric peptide agonists.
Can orforglipron be combined with other weight loss medications?
Most evidence supports combining orforglipron with mechanism-distinct agents rather than other GLP-1 agonists (which would be redundant). Leading combinations: (1) amylin analog like Cagrilintide — Novo Nordisk's CagriSema concept shows ~22.7% weight loss with semaglutide + cagrilintide; orforglipron + cagrilintide should produce similar synergy; (2) SGLT2 inhibitors for T2D — complementary mechanisms with additive glycemic and weight benefits; (3) metformin — standard T2D foundation. Avoid combining orforglipron with other GLP-1 agonists, other allosteric GLP-1 modulators, or Tirzepatide / Retatrutide / Mazdutide, which would be pharmacologically redundant at the GLP-1 receptor.
What side effects should I expect on orforglipron?
Expect gastrointestinal symptoms similar to all GLP-1 agonists: nausea (30-50% at therapeutic doses), diarrhea or constipation (20-30%), vomiting (10-20%), reduced appetite (expected therapeutic effect but can feel uncomfortable early). These usually peak during dose escalations and improve within 1-2 weeks at each step. The standard 4-week titration (3 mg → 12 mg → 24 mg → 36 mg) significantly reduces intolerance versus faster escalation. Less common but serious: pancreatitis (rare, requires evaluation if severe abdominal pain develops), gallbladder disease (weight loss-related), retinopathy worsening (in patients with existing diabetic retinopathy during rapid glycemic improvement). Long-term theoretical concerns include medullary thyroid carcinoma (rodent signal, no clear human signal), warranting the MTC/MEN2 contraindication shared across the GLP-1 class (Frías et al., 2023).
Will I regain weight if I stop taking orforglipron?
Yes, most patients regain substantial weight within 12 months of discontinuation. This mirrors the pattern seen with semaglutide (STEP-4 extension trial: ~2/3 of weight regained by 1 year off-drug) and tirzepatide (SURMOUNT-4: similar pattern). GLP-1 agonists are best understood as chronic therapy for chronic disease — analogous to how antihypertensives control blood pressure only while taken. Patients considering orforglipron should plan for long-term or lifelong therapy, with structured lifestyle support (resistance training, protein-forward nutrition, sleep optimization) to maximize the weight maintained if discontinuation becomes necessary. Some patients successfully transition to maintenance doses (e.g., 12 mg daily instead of 36 mg) to sustain partial benefit at lower cost and side effects.
How does orforglipron affect body composition versus just total weight?
Like all GLP-1 agonists, orforglipron produces primarily fat-mass loss but also some lean-mass loss — typically 20-40% of total weight lost is lean tissue. This is a well-documented class effect seen with semaglutide (STEP-1 DEXA substudy), tirzepatide (SURMOUNT DEXA data), and expected for orforglipron. Mitigation strategies include: (1) resistance training 2-3x/week minimum — the single most impactful intervention for lean mass preservation; (2) high-protein intake of 1.2-1.6 g/kg body weight daily; (3) adequate overall calories to support muscle protein synthesis; (4) consideration of adjunctive growth-hormone-axis support such as Tesamorelin, Ipamorelin, or CJC-1295 for patients prioritizing lean mass preservation. DEXA scans every 6-12 months allow objective tracking of body composition changes rather than relying on scale weight alone.
Is orforglipron safe for people with type 1 diabetes?
Orforglipron is not indicated for type 1 diabetes. Its primary mechanisms — glucose-dependent insulin secretion and glucagon suppression — require functional pancreatic beta cells, which T1D patients lack. Using orforglipron in T1D risks diabetic ketoacidosis (DKA) if insulin doses are inappropriately reduced in response to modest glycemic improvement, and the drug adds complexity without clear benefit. Some T1D patients with obesity have explored off-label GLP-1 agonist use to support weight loss with variable results and increased complexity; this should only be done with close endocrinology supervision and intensive monitoring. FDA approval for orforglipron is for T2D and obesity only; T1D use would be off-label and experimental.
Why is orforglipron a big deal beyond just being oral?
The transformational implications extend beyond convenience: (1) Manufacturing scale: small-molecule synthesis uses existing generic drug manufacturing infrastructure, potentially eliminating the peptide supply crisis that caused 2+ year semaglutide shortages and limited tirzepatide rollout; (2) Global access: no cold-chain requirement means distribution to low- and middle-income countries becomes feasible — currently injectable GLP-1s are essentially unavailable across much of Africa, South America, and Southeast Asia due to refrigeration logistics; (3) Cost reduction: generic competition after patent expiration (mid-2030s) could bring retail cost from $1,000+/month to potentially $20-50/month, analogous to how statins democratized cholesterol management; (4) Patient barrier removal: ~30-40% of candidates for injectable GLP-1s decline due to needle aversion; orforglipron removes this barrier entirely; (5) Development platform: success validates allosteric small-molecule peptide-receptor agonism as a drug discovery strategy, opening the door to oral versions of other peptide drug classes (e.g., GIP agonists, glucagon agonists, incretin combinations). If the FDA approves orforglipron in 2026, it will mark the beginning of the oral GLP-1 era and likely the peak of the injectable-peptide era — a shift with major public health consequences.
Research Tools
Related Compounds
View All5-Amino-1MQ
Weight LossPreclinical5-Amino-1MQ (5-amino-1-methylquinolinium iodide) is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme that transfers a methyl group from S-adenosyl-L-methionine (SAM) to nicotinamide to form 1-methylnicotinamide (1-MNA) and S-adenosyl-L-homocysteine (SAH).
BAM15
Weight LossPreclinicalBAM15 is a small-molecule mitochondrial protonophore uncoupler that was first described in 2014 as a tool compound for dissipating proton motive force selectively across the inner mitochondrial membrane without collapsing the plasma membrane electrochemical gradient (Kenwood et al., 2014).
Exenatide
Weight LossPreclinicalGLP-1 receptor agonist used for metabolic effect and appetite regulation..
L-Carnitine
Weight LossPreclinicalL-Carnitine is a naturally occurring quaternary ammonium compound synthesized in the body from the amino acids lysine and methionine, with essential cofactor roles in fatty acid metabolism, energy production, and cellular health.
Lipo-C
Weight LossPreclinicalLipotropic compound blend injection.
Mazdutide
Weight LossPreclinicalMazdutide (also known as IBI362, Lilly compound LY3305677) is a dual glucagon-like peptide-1 (GLP-1) and glucagon receptor agonist originally discovered by Eli Lilly and exclusively licensed to Innovent Biologics in 2019 for development and commercialization in Mainland China, Hong Kong, Macau, and Taiwan.
Side-by-Side Comparisons
All ComparisonsCompare Orforglipron head-to-head: mechanism, half-life, dosing, safety, and live pricing.
Free 2026 Peptide Cheat Sheet — 50 pages, PDF
Dosing, reconstitution, stacks, half-lives, and vendor trust tiers. The reference we wish we had on day one.
